EIGRQ
Price:
$8.5
Market Cap:
$12.59M
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. The company offers Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies. Its product candidates include Lonafarnib, an orally available, farnesylation inhibitor, which has completed Phase 3 clinical trials for HDV infection; Peginterferon Lambda (lambda), which is in clinical development for HDV; lambda, that is in phase II and III investigator studies of mild and moderate COVID-19; and Avexitide, which is in Phase II for the treatment of congenital hyperi...[Read more]
Industry
Biotechnology
IPO Date
2014-01-30
Stock Exchange
OTC
Ticker
EIGRQ
According to Eiger BioPharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -367.00%. This represents a change of -244.32% compared to the average of 254.29% of the last 4 quarters.
The mean historical ROE of Eiger BioPharmaceuticals, Inc. over the last ten years is -34.87%. The current -367.00% ROE has changed 952.53% with respect to the historical average. Over the past ten years (40 quarters), EIGRQ's ROE was at its highest in in the September 2023 quarter at 1.12%. The ROE was at its lowest in in the June 2023 quarter at -135.31%.
Average
-34.87%
Median
-97.15%
Minimum
-188.47%
Maximum
518.49%
Discovering the peaks and valleys of Eiger BioPharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 273.49%
Maximum Annual ROE = 518.49%
Minimum Annual Increase = -396.33%
Minimum Annual ROE = -188.47%
Year | ROE | Change |
---|---|---|
2023 | 518.49% | -396.33% |
2022 | -174.97% | 273.49% |
2021 | -46.85% | -31.56% |
2020 | -68.45% | -44.97% |
2019 | -124.38% | 58.10% |
2018 | -78.67% | -58.26% |
2017 | -188.47% | 62.99% |
The current ROE of Eiger BioPharmaceuticals, Inc. (EIGRQ) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
98.89%
5-year avg
20.77%
10-year avg
-34.87%
Eiger BioPharmaceuticals, Inc.’s ROE is
Company | ROE | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Eiger BioPharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Eiger BioPharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Eiger BioPharmaceuticals, Inc.'s ROE?
How is the ROE calculated for Eiger BioPharmaceuticals, Inc. (EIGRQ)?
What is the highest ROE for Eiger BioPharmaceuticals, Inc. (EIGRQ)?
What is the 3-year average ROE for Eiger BioPharmaceuticals, Inc. (EIGRQ)?
What is the 5-year average ROE for Eiger BioPharmaceuticals, Inc. (EIGRQ)?
How does the current ROE for Eiger BioPharmaceuticals, Inc. (EIGRQ) compare to its historical average?